达格列净联合沙库巴曲缬沙坦治疗射血分数降低的心力衰竭患者的疗效

doi:10.20223/j.cnki.1000-8535.2025.07.020

摘要/Abstract

摘要： 目的分析达格列净联合沙库巴曲缬沙坦治疗射血分数降低的心力衰竭（HFrEF）效果。方法连续抽取2021年1月—2023年6月在广州市第一人民医院心内科住院的射血分数降低的心力衰竭（HFrEF）患者203例,随访至少6个月,按照接受的治疗进行分组。对照组予常规治疗和沙库巴曲缬沙坦治疗;观察组予常规治疗、沙库巴曲缬沙坦和达格列净治疗;对比两组疗效,观察指标包括住院时间,入院及出院后6个月的心功能状态（NYHA纽约心脏病协会心功能分级）、心脏超声指标左室射血分数（LVEF）、左室舒张末内径（LVEDD）、左室收缩末内径（LVSDD）、血液指标-端脑钠肽前体（NT-proBNP N）、糖化血红蛋白（HBA1c）、血肌酐（Cr）、6个月时的再住院率及全因死亡率。结果观察组心脏监护病房（CCU）停留时间（2.54±1.26）d,短于对照组的（3.73±1.21）d;观察组6个月时观察组心功能NYHA改善≥2级比例为95.05%高于对照组的86.27%,差异有统计学意义（P<0.05）;观察组6个月时的LVEDD、LVESD水平分别为（48.22±7.35）（34.61±4.32）mm,低于对照组的（51.47±8.02）（43.07±5.33）mm,LVEF为（51.49±5.40）%,高于对照组的（46.18±4.21）%,差异有统计学意义（P<0.05）;6个月时观察组的NT-proBNP为（415.58±31.57）pg/mL,低于对照组的（520.23±385.56）pg/mL,差异有统计学意义（P<0.05）;两组的住院时间、血清肌酐（Cr）、HBA1c、6个月时的再住院率、全因病死率对比,差异不显著（P>0.05）。观察组HBA1c值为（6.04±0.66）mmol/L,高于对照组的（5.20±0.56）mmol/L（P<0.05）。结论 HFrEF患者采取达格列净+沙库巴曲缬沙坦治疗,可通过协同作用,缩短CCU停留时间,改善患者6个月时的心功能状态,降低NT-proBNP值,减少心脏扩大趋势,提高LVEF水平。

关键词: HFrEF, 达格列净, 沙库巴曲缬沙坦

Abstract: Objective To analyze the efficacy of dapagliflozin combined with sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction（HFrEF）．Methods A total of 203 patients with HFrEF who were hospitalized in the cardiology department of the hospital between January 2021 and June 2023 were enrolled and followed up for at least six months．Patients were divided into groups based on their treatment regimens：the control group received conventional treatment plus sacubitril/valsartan,while the observation group received conventional treatment plus sacubitril/valsartan and dapagliflozin．The two groups were compared for clinical outcomes,including length of hospital stay,cardiac function（NYHA classification）at admission and six months after discharge,echocardiographic indicators（LVEF,LVEDD,LVESD）,blood indicators（NT-proBNP,HbA1c,creatinine）,six-month rehospitalization rate,and all-cause mortality．Results The observation group had a shorter CCU stay（2.54±1.26 days）compared to the control group（3.73±1.21 days）．At sixth month,the proportion of patients in the observation group with an NYHA improvement ≥2 grades（95.05%）was significantly higher than that in the control group（86.27%）（P<0.05）．The observation group demonstrated lower LVEDD（48.22±7.35 mm）and LVESD（34.61±4.32 mm）levels and higher LVEF（51.49±5.40%）compared to the control group（LVEDD：[51.47±8.02] mm,LVESD：[43.07±5.33] mm,LVEF：[46.18±4.21]%）（P<0.05）．NT-proBNP levels in the observation group（[415.58±31.57] pg/mL）were significantly lower than those in the control group（[520.23±385.56] pg/ml）（P<0.05）．There were no significant differences between the two groups in length of total hospital stay,serum creatinine,HbA1c,six-month rehospitalization rate,or all-cause mortality（P>0.05）．However,HbA1c levels in the observation group（[6.04±0.66] mmol/L）were higher than those in the control group（[5.20±0.56] mmol/L）（P<0.05）．Conclusions The combination of dapagliflozin and sacubitril/valsartan in the treatment of HFrEF patients can exert a synergistic effect,shorten CCU stay,improve cardiac function at sixth month,reduce NT-proBNP levels,mitigate cardiac dilation,and increase LVEF．

Key words: HFrEF, dapagliflozin, sacubitril/valsartan

谭文亮, 吴天源, 刘震. 达格列净联合沙库巴曲缬沙坦治疗射血分数降低的心力衰竭患者的疗效[J]. 广州医药, 2025, 56(7): 988-994.

TAN Wenliang, WU Tianyuan, LIU Zhen. Efficacy of dapagliflozin combined with sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction[J]. Guangzhou Medical Journal, 2025, 56(7): 988-994.

参考文献

[1] 陈瑞敏,刘放,谈红,等.达格列净对2型糖尿病合并慢性心力衰竭患者微小RNA-423-5p的调控作用及心功能的影响研究[J].中国全科医学,2023,26(14):1733-1738.
[2] 卜星彭,刘雅茹,李丽,等.达格列净对老年射血分数保留的心力衰竭患者肠道微生物代谢产物及炎性因子的影响[J].中华老年心脑血管病杂志,2022,24(11):1215-1217.
[3] 王建丽,周琳,肖小玲,等.沙库巴曲缬沙坦联合达格列净对射血分数减低型心衰不伴糖尿病患者的疗效[J].西安交通大学学报(医学版),2023,44(3):415-420.
[4] 张晓旭,杨文奇.沙库巴曲缬沙坦治疗AMI后射血分数中间值心力衰竭的疗效研究[J].天津医药,2024,52(2):177-181.
[5] 韩丽珠,尹琪楠,边原,等.2022AHA/ACC/HFSA心力衰竭管理指南解读[J].医药导报,2023,42(9):1280-1287.
[6] 马赛,左庆娟,张国瑞,等.钠氢交换体可能是钠-葡萄糖共转运蛋白2抑制剂心力衰竭获益及不良反应的潜在靶点[J].心血管病学进展,2021,42(8):686-690.
[7] 吴荣荣,朱映红,马红丽,等.达格列净对高血压合并糖尿病、心力衰竭患者脂代谢、心功能及血清微小RNA的影响[J].中华高血压杂志,2023,31(1):85-90.
[8] 郑黄生. 钠-葡萄糖协同转运蛋白-2抑制剂治疗射血分数降低心力衰竭的疗效及预后分析[D].合肥:安徽医科大学,2021.
[9] 杨杰孚,王华,柴坷.2018中国心力衰竭诊断和治疗指南亮点[J].中国心血管病研究,2018,16(12):1057-1060.
[10] 上官秋圆,董璐怡.沙库巴曲缬沙坦治疗慢性心力衰竭患者预后的影响因素分析[J].中华老年心脑血管病杂志,2023,25(7):708-711.
[11] 孙红春,李敬,高茜,等.沙库巴曲缬沙坦和托伐普坦对慢性心力衰竭急性发作患者炎性指标的影响[J].中华老年心脑血管病杂志,2023,25(5):469-472.
[12] 高燕,朱庆颖,栾明亚,等.托伐普坦联合达格列净对心衰大鼠心肌纤维化的影响[J].山东大学学报(医学版),2022,60(12):13-18,25.
[13] MCMURRAY J J V,WHEELER D C,STEFANSSON B V,et al.Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease,with and without cardiovascular disease[J].Circulation,2021,143(5):438-448.
[14] 张春霞,罗洋,周晓玲,等.沙库巴曲缬沙坦对老年维持性血液透析患者慢性心力衰竭疗效的临床研究[J].中华老年心脑血管病杂志,2023,25(1):20-23.
[15] 林郁峰,侯成民,张娟平.沙库巴曲缬沙坦治疗射血分数中间值心力衰竭患者的临床疗效观察[J].中华老年心脑血管病杂志,2022,24(6):587-590.
[16] 刘侃玲,张瑶.达格列净对老年急性心肌梗死后心力衰竭患者心功能及MACE的影响[J].解放军医学杂志,2023,48(12):1427-1432.
[17] 尹佳伊黎. 达格列净结合沙库巴曲缬沙坦对糖尿病合并心力衰竭患者的疗效及相关影响因素分析[J].中国医药指南,2024,22(22):65-68.
[18] 杨薪,蔡学坤,吴泽龙,等.达格列净对慢性心力衰竭大鼠心肌细胞基质金属蛋白酶及其组织抑制因子-1水平的影响[J].中国临床药理学杂志,2023,39(8):1104-1107.
[19] 王要鑫,刘洁云,秦雷,等.达格列净在非糖尿病老年患者急性ST段抬高型心肌梗死PPCI术后的近期疗效观察[J].临床心血管病杂志,2023,39(2):126-129.
[20] 郭一丁. 达格列净辅助治疗老年心力衰竭合并T2DM患者的效果[J].广州医药,2023,54(3):101-104.
[21] 刘青,赵志杰,刘仁富,等.血清PTEN、CD34和NT-proBNP在老年心力衰竭早期诊断及预后评估中的应用[J].疑难病杂志,2023,22(11):1143-1147.
[22] 陈曦. 沙库巴曲缬沙坦联合达格列净治疗心力衰竭的疗效及对血清NT-proBNP、炎症因子的影响[J].心血管病防治知识,2024,14(11):70-73.
[23] 蔡涛,蓝晓红,孙兰珍,等.达格列净联合沙库巴曲缬沙坦对经皮冠状动脉介入治疗术后心力衰竭患者炎性因子的影响及预后影响因素分析[J].中国心血管病研究,2024,22(9):837-841.
[24] 张俊仕,张颖,孙理华,等.老年心力衰竭患者血浆galectin-3表达与心脏结构、功能的关系[J].中华生物医学工程杂志,2020,26(5):412-416.
[25] 王莲莲,马丽莉.达格列净联合沙库巴曲缬沙坦治疗老年急性心肌梗死后心衰的疗效及对Galectin-3、TMAO、CRP、BNP水平的影响[J].中南医学科学杂志,2023,51(6):868-871.